<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336307</url>
  </required_header>
  <id_info>
    <org_study_id>s001</org_study_id>
    <nct_id>NCT03336307</nct_id>
  </id_info>
  <brief_title>Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation</brief_title>
  <official_title>Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Parkinson's disease show a gait disturbance which is considered as one of the
      most disabling aspect of the disease that strongly impacts on patients' autonomy and quality
      of life. The mechanism underlying gait impairment is multi-factorial, reflects the global
      motor impairment of patients with PD and is mainly related to a neurotransmitter deficiency
      inducing bradykinesia, rigidity, abnormal trunk control and postural instability. For this
      reason, and considering the impact of social and economic costs, one of the main foci of
      intervention in patients with PD should be treating gait abnormalities. This need is further
      reinforced by the knowledge that gait outcomes are correlated with longevity, cognitive
      decline and adverse events.

      Besides the shorten-step gait clinical description of the gait disorder in PD, in the last
      years, studies using modern 3D motion analysis systems have further detailed the gait pattern
      in PD disclosing abnormalities in cadence, stance duration, swing duration, double support
      duration, leg length, step length, velocity, hip, knee and ankle ROMs. Such abnormal gait
      parameters seem to correlate with the clinical outcomes of UPDRS score, H-Y stage and
      milliequivalents of levodopa taken. Importantly, gait parameters can either normalize or
      improve after several rehabilitative treatment strategies including physiotherapy, assistive
      equipment, sensory cueing, treadmill training, physical activity, home base exercises.
      However, none of the previous studies specifically investigated which biomechanical factor
      can be modified after rehabilitation and which clinical characteristic can predict the
      rehabilitation-induced gait improvement. This would be extremely important to typifying,
      grouping and selecting patients, optimizing the rehabilitative strategies and cost
      management.

      The aims of the present study were to evaluate in a sample of patients with PD: i) which gait
      parameters can be modified after a short-term rehabilitation program; ii) which, if any,
      clinical variable can predict the improvement of the gait function after rehabilitation. At
      this aim we quantitatively evaluated the gait performance of PD patients by means of a 3-D
      motion analysis system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty out of 67 patients with idiopathic PD assessed for eligibility were recruited at
      Rehabilitation Unit of Department of Medical and Surgical Sciences and Biotechnologies,
      University of Rome, Sapienza, and at Rehabilitation Unit of Policlinico Italia Centre, Rome,
      Italy. Patients were admitted for outpatient rehabilitation between May 2014 and April 2017.
      The inclusion criteria were a diagnosis of idiopathic PD according to UK bank criteria and
      Hoehn and Yahr stages 1 to 3. All patients were in a stable drug program and had adapted to
      their current medications for at least 2 weeks. Exclusion criteria were: cognitive deficits
      (defined as scores of &lt;26 on the Mini-Mental State Examination [MMSE]), moderate or severe
      depression (defined as scores of &gt;17 on the Beck Depression Inventory [BDI]), and orthopedic
      and other gait-influencing diseases such as arthrosis or total hip joint replacement.

      All participants could walk independently without walking devices. All patients were taking
      oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13
      patients) and were recorded in on phase.

      Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale
      (UPDRS-II and III) and the Hoehn and Yahr staging system.

      The study complied with the Helsinki Declaration and received local ethics committee
      approval. Prior to taking part in the study, all the participants gave a written consent
      after a fully explanation of the experimental procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>stance duration (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>time interval between two consecutive foot strikes of the same lower limb) expressed as a percentage of the stride duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>step length (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>the distance measured from the heel print of one foot to the heel print of the other foot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step width (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>Step width variability discriminates gait of healthy young and older adults during treadmill locomotion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>walking speed (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>distance coverde by the body in unit of time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cadence (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>time of steps per unit time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The flexion-extension hips (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trunk saggital plane (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trunk frotal plane (change)</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale UPDRS Severity of parkinsonism</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>The UPDRS is made up of these sections:
Part I: evaluation of mentation, behavior, and mood
Part II: self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
Part III: clinician-scored monitored motor evaluation
Part IV: complications of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Hoehn and Yahr staging</measure>
    <time_frame>- T0 at baseline before rehabilitative treatment - T1 10- week after rehabilitative treatments</time_frame>
    <description>Unilateral involvement only usually with minimal or no functional disability Unilateral involvement only 1.5 - Unilateral and axial involvement
Bilateral or midline involvement without impairment of balance Bilateral involvement without impairment of balance 2.5 - Mild bilateral disease with recovery on pull test
Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent Mild to moderate bilateral disease; some postural instability; physically independent
Severely disabling disease; still able to walk or stand unassisted Severe disability; still able to walk or stand unassisted
Confinement to bed or wheelchair unless aided Wheelchair bound or bedridden unless aided</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with Parkinson's disease</arm_group_label>
    <description>All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.
Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.
All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation program</intervention_name>
    <description>all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:
endurance, strength, flexibility and balance with functional practice for all H/Y stage
endurance also for H/Y stage 1,
motor learning principles and cue functional for H/Y stage 2-3
external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk).</description>
    <arm_group_label>Patients with Parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Fifty out of 67 patients with idiopathic PD assessed for eligibility were recruited at
        Rehabilitation Unit of Department of Medical and Surgical Sciences and Biotechnologies,
        University of Rome, Sapienza, and at Rehabilitation Unit of Policlinico Italia Centre,
        Rome, Italy. Patients were admitted for outpatient rehabilitation between May 2014 and
        April 2017. All patients were in a stable drug program and had adapted to their current
        medications for at least 2 weeks.

        All participants could walk independently without walking devices. All patients were taking
        oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13
        patients) and were recorded in on phase. Patients' clinical and anthropometric
        characteristics.

        Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale
        (UPDRS-II and III) and the Hoehn and Yahr staging system.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic PD according to UK bank criteria

          -  Hoehn and Yahr stages 1 to 3.

          -  All patients were in a stable drug program and had adapted to their current
             medications for at least 2 weeks

        Exclusion Criteria:

          -  Cognitive deficits (defined as scores of &lt;26 on the Mini-Mental State Examination
             [MMSE]),

          -  moderate or severe depression (defined as scores of &gt;17 on the Beck Depression
             Inventory [BDI]), -. orthopedic and other gait-influencing diseases such as arthrosis
             or total hip joint replacement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Caramanico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† &quot;La Sapienza di Roma&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Italia Srl</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Meunier S, Pol S, Houeto JL, Vidailhet M. Abnormal reciprocal inhibition between antagonist muscles in Parkinson's disease. Brain. 2000 May;123 ( Pt 5):1017-26.</citation>
    <PMID>10775546</PMID>
  </reference>
  <reference>
    <citation>Pistacchi M, Gioulis M, Sanson F, De Giovannini E, Filippi G, Rossetto F, Zambito Marsala S. Gait analysis and clinical correlations in early Parkinson's disease. Funct Neurol. 2017 Jan/Mar;32(1):28-34.</citation>
    <PMID>28380321</PMID>
  </reference>
  <reference>
    <citation>Vieregge P, Stolze H, Klein C, Heberlein I. Gait quantitation in Parkinson's disease--locomotor disability and correlation to clinical rating scales. J Neural Transm (Vienna). 1997;104(2-3):237-48.</citation>
    <PMID>9203085</PMID>
  </reference>
  <reference>
    <citation>Pau M, Corona F, Pili R, Casula C, Sors F, Agostini T, Cossu G, Guicciardi M, Murgia M. Effects of Physical Rehabilitation Integrated with Rhythmic Auditory Stimulation on Spatio-Temporal and Kinematic Parameters of Gait in Parkinson's Disease. Front Neurol. 2016 Aug 11;7:126. doi: 10.3389/fneur.2016.00126. eCollection 2016.</citation>
    <PMID>27563296</PMID>
  </reference>
  <reference>
    <citation>Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord. 2009 Jan 15;24(1):1-14. doi: 10.1002/mds.22141. Review.</citation>
    <PMID>18946880</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Mariano Serrao</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>movement Disorders</keyword>
  <keyword>gait disturbance</keyword>
  <keyword>Parkinson</keyword>
  <keyword>Parkinson gait</keyword>
  <keyword>3D motion analysis systems</keyword>
  <keyword>motion analysis</keyword>
  <keyword>Parkinson rehabilitation</keyword>
  <keyword>rehabilitation gait improvement</keyword>
  <keyword>gait improvement</keyword>
  <keyword>SMART Capture</keyword>
  <keyword>MATLAB software</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

